Fibromyalgia (FM) is a common, chronic, widespread pain disorder that is estimated to impact 0.5% to 5% of the population worldwide. In the United States, more than 5 million individuals are thought to be affected, and it is the second most common disorder observed by rheumatologists (after osteoarthritis). Fibromyalgia is defined by the American College of Rheumatology (ACR) as a condition characterized by widespread pain and tenderness, and patients with fibromyalgia report severe fatigue, described as being physically or emotionally draining. Fibromyalgia patients also have significantly more mental distress, including depression, anxiety, and dyscognition. Women currently account for 80% to 90% of cases diagnosed by the ACR criteria.
The standard of care for fibromyalgia includes both non-pharmacologic (exercise, education, and cognitive-behavioral therapy) and pharmacologic approaches.
To request more information about clinical trials and fibromyalgia, please submit the form below.